{"success":true,"data":{"pressRelease":{"id":"168930","rtpr_id":"nGNX5JZh41-20261014","ticker":"PPCB","exchange":"NASDAQ","all_tickers":["PPCB"],"title":"Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer","author":"Globe Newswire","published_at":"2026-10-14T12:30:00.377Z","article_body":"MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,\nInc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical\ncompany focused on developing novel treatments for chronic diseases including\nrecurrent and metastatic cancer, today announced the publication of a\npeer-reviewed pilot study in Scientific Reports (Nature Publishing Group)\ntitled “A formulation of pancreatic pro-enzymes provides potent anti-tumor\nefficacy: a pilot study focused on pancreatic and ovarian cancer.”\n\nThe study evaluates PRP, the Company’s proprietary fixed-ratio combination\nof the pancreatic proenzymes Trypsinogen and Chymotrypsinogen A (1:6). Across\n24 human cancer cell lines, the 1:6 ratio demonstrated synergistic growth\ninhibition relative to other ratios. In summary:\n* Anti-angiogenic activity: PRP dose-dependently blocked tube formation by\nhuman umbilical vein endothelial cells without affecting viability. In the in\nvivo AngioChamber™ assay, PRP reduced bFGF-driven fibrous capsule formation\nby 57% versus induction controls.\n* Anti-metastatic effects: PRP significantly inhibited cell migration in\nwound-healing assays (pancreatic, ovarian, melanoma and colon lines) and\nproduced near-complete, dose-dependent blockade of invasion through Matrigel\nin pancreatic and colon cancer cells.\n* EMT reversal: In BxPC3 pancreatic and A2780 ovarian cells, PRP increased\nepithelial marker E-cadherin while decreasing mesenchymal markers N-cadherin,\nSlug and vimentin. Immunofluorescence confirmed increased membrane\nlocalization of E-cadherin and β-catenin.\n* Orthotopic efficacy: Daily intravenous PRP produced an 85.9% reduction in\nmean tumor weight in a syngeneic orthotopic pancreatic (Pan02) model at the\nhigher dose and ~50% tumor-weight inhibition in an orthotopic ovarian (A2780)\nmodel across two dose levels. Treatment was well tolerated with no\ntreatment-related adverse clinical events.\n* Clinical signals via UK Specials Scheme: In 46 patients with advanced,\nmostly metastatic cancers of various origins treated with a rectal proenzyme\nformulation, 19 patients (41.3%) survived longer than predicted life\nexpectancy. Across the cohort, mean survival was 9.0 months versus a mean\nexpected survival of 5.6 months (p < 0.05). No severe or serious adverse\nevents related to rectal administration, hematologic toxicity, or allergic\nreactions were observed.\n“The data published in Scientific Reports provide clear evidence that our\nsynergistic PRP formulation can inhibit key drivers of tumor\nprogression—angiogenesis, invasion and epithelial-to-mesenchymal\ntransition—while delivering meaningful tumor growth suppression in relevant\northotopic models,” said Dr. Ralf Brandt, Propanc’s Research and\nDevelopment Director. “The encouraging survival extension observed in the UK\nSpecials program, together with the favorable tolerability profile, supports\ncontinued development of PRP as a differentiated, non-cytotoxic approach for\npatients with advanced pancreatic adenocarcinoma and epithelial ovarian\ncancer.”\n\nPRP is designed as a long-term therapy to reduce the risk of tumor recurrence\nand metastasis—the primary cause of death in solid tumors. The Company’s\ninitial target indications include pancreatic, ovarian and refractory prostate\ncancers, areas of high unmet need with limited durable treatment options.\n\nAbout Propanc Biopharma, Inc.\n\nPropanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to\npreventing cancer recurrence and metastasis by targeting and eradicating\ncancer stem cells through proenzyme activation. The Company’s lead product\ncandidate, PRP, is designed to address the underlying drivers of cancer\nproliferation and spread.\n\nMore information: www.propanc.com\n\nForward-Looking Statements\n\nAll statements in this press release that are not historical are\nforward-looking statements, including, among other things, statements relating\nto the Company’s expectations regarding its market position and market\nopportunity, expectations and plans as to its product development,\nmanufacturing and sales, and relations with its partners and investors, made\nin reliance upon the safe harbor provisions of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of\n1934, as amended. These statements are not historical facts but rather are\nbased on the Company’s current expectations, estimates, and projections\nregarding its business, operations and other similar or related factors. Words\nsuch as “may,” “will,” “could,” “would,” “should,”\n“anticipate,” “predict,” “potential,” “continue,”\n“expect,” “intend,” “plan,” “project,” “believe,”\n“estimate,” and other similar or related expressions are used to identify\nthese forward-looking statements, although not all forward-looking statements\ncontain these words. You should not place undue reliance on forward-looking\nstatements because they involve known and unknown risks, uncertainties, and\nassumptions that are difficult or impossible to predict and, in some cases,\nbeyond the Company’s control. Forward-looking statements are not guarantees\nof future actions or performance. Actual results may differ materially from\nthose in the forward-looking statements because of several factors, including,\nwithout limitation, risks and uncertainties related to market conditions, as\nwell as those risks described under “Risk Factors” in the prospectus\nrelated to the proposed offering and those described in the Company’s\nfilings with the SEC. The Company undertakes no obligation to revise or update\ninformation in this release to reflect events or circumstances in the future,\neven if new information becomes available.\n\nCompany:\nPropanc Biopharma, Inc.\nJames Nathanielsz\n\n+61-3-9882-0780\ninfo@propanc.com\n\nInvestor Contact:\nirteam@propanc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5JZh41-20261014","title":"Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer","author":"Globe Newswire","ticker":"PPCB","created":"2026-10-14T12:30:00.377Z","tickers":["PPCB"],"exchange":"NASDAQ","article_body":"MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,\nInc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical\ncompany focused on developing novel treatments for chronic diseases including\nrecurrent and metastatic cancer, today announced the publication of a\npeer-reviewed pilot study in Scientific Reports (Nature Publishing Group)\ntitled “A formulation of pancreatic pro-enzymes provides potent anti-tumor\nefficacy: a pilot study focused on pancreatic and ovarian cancer.”\n\nThe study evaluates PRP, the Company’s proprietary fixed-ratio combination\nof the pancreatic proenzymes Trypsinogen and Chymotrypsinogen A (1:6). Across\n24 human cancer cell lines, the 1:6 ratio demonstrated synergistic growth\ninhibition relative to other ratios. In summary:\n* Anti-angiogenic activity: PRP dose-dependently blocked tube formation by\nhuman umbilical vein endothelial cells without affecting viability. In the in\nvivo AngioChamber™ assay, PRP reduced bFGF-driven fibrous capsule formation\nby 57% versus induction controls.\n* Anti-metastatic effects: PRP significantly inhibited cell migration in\nwound-healing assays (pancreatic, ovarian, melanoma and colon lines) and\nproduced near-complete, dose-dependent blockade of invasion through Matrigel\nin pancreatic and colon cancer cells.\n* EMT reversal: In BxPC3 pancreatic and A2780 ovarian cells, PRP increased\nepithelial marker E-cadherin while decreasing mesenchymal markers N-cadherin,\nSlug and vimentin. Immunofluorescence confirmed increased membrane\nlocalization of E-cadherin and β-catenin.\n* Orthotopic efficacy: Daily intravenous PRP produced an 85.9% reduction in\nmean tumor weight in a syngeneic orthotopic pancreatic (Pan02) model at the\nhigher dose and ~50% tumor-weight inhibition in an orthotopic ovarian (A2780)\nmodel across two dose levels. Treatment was well tolerated with no\ntreatment-related adverse clinical events.\n* Clinical signals via UK Specials Scheme: In 46 patients with advanced,\nmostly metastatic cancers of various origins treated with a rectal proenzyme\nformulation, 19 patients (41.3%) survived longer than predicted life\nexpectancy. Across the cohort, mean survival was 9.0 months versus a mean\nexpected survival of 5.6 months (p < 0.05). No severe or serious adverse\nevents related to rectal administration, hematologic toxicity, or allergic\nreactions were observed.\n“The data published in Scientific Reports provide clear evidence that our\nsynergistic PRP formulation can inhibit key drivers of tumor\nprogression—angiogenesis, invasion and epithelial-to-mesenchymal\ntransition—while delivering meaningful tumor growth suppression in relevant\northotopic models,” said Dr. Ralf Brandt, Propanc’s Research and\nDevelopment Director. “The encouraging survival extension observed in the UK\nSpecials program, together with the favorable tolerability profile, supports\ncontinued development of PRP as a differentiated, non-cytotoxic approach for\npatients with advanced pancreatic adenocarcinoma and epithelial ovarian\ncancer.”\n\nPRP is designed as a long-term therapy to reduce the risk of tumor recurrence\nand metastasis—the primary cause of death in solid tumors. The Company’s\ninitial target indications include pancreatic, ovarian and refractory prostate\ncancers, areas of high unmet need with limited durable treatment options.\n\nAbout Propanc Biopharma, Inc.\n\nPropanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to\npreventing cancer recurrence and metastasis by targeting and eradicating\ncancer stem cells through proenzyme activation. The Company’s lead product\ncandidate, PRP, is designed to address the underlying drivers of cancer\nproliferation and spread.\n\nMore information: www.propanc.com\n\nForward-Looking Statements\n\nAll statements in this press release that are not historical are\nforward-looking statements, including, among other things, statements relating\nto the Company’s expectations regarding its market position and market\nopportunity, expectations and plans as to its product development,\nmanufacturing and sales, and relations with its partners and investors, made\nin reliance upon the safe harbor provisions of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of\n1934, as amended. These statements are not historical facts but rather are\nbased on the Company’s current expectations, estimates, and projections\nregarding its business, operations and other similar or related factors. Words\nsuch as “may,” “will,” “could,” “would,” “should,”\n“anticipate,” “predict,” “potential,” “continue,”\n“expect,” “intend,” “plan,” “project,” “believe,”\n“estimate,” and other similar or related expressions are used to identify\nthese forward-looking statements, although not all forward-looking statements\ncontain these words. You should not place undue reliance on forward-looking\nstatements because they involve known and unknown risks, uncertainties, and\nassumptions that are difficult or impossible to predict and, in some cases,\nbeyond the Company’s control. Forward-looking statements are not guarantees\nof future actions or performance. Actual results may differ materially from\nthose in the forward-looking statements because of several factors, including,\nwithout limitation, risks and uncertainties related to market conditions, as\nwell as those risks described under “Risk Factors” in the prospectus\nrelated to the proposed offering and those described in the Company’s\nfilings with the SEC. The Company undertakes no obligation to revise or update\ninformation in this release to reflect events or circumstances in the future,\neven if new information becomes available.\n\nCompany:\nPropanc Biopharma, Inc.\nJames Nathanielsz\n\n+61-3-9882-0780\ninfo@propanc.com\n\nInvestor Contact:\nirteam@propanc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T12:30:00.448668923Z","server_sent_at_ms":1791981000448},"received_at":"2026-10-14T12:30:00.525Z","source_url":null},"analysis":{"id":"157183","press_release_id":"168930","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["clinical signals are from a retrospective UK Specials program, not a controlled trial","data are primarily preclinical; no pivotal human efficacy study yet"],"eventType":"clinical_trial","narrative":"Propanc Biopharma announced publication of a peer-reviewed pilot study in Scientific Reports showing potent anti-tumor efficacy of its PRP pancreatic proenzyme formulation across 24 human cancer cell lines.\n\nIn orthotopic mouse models, daily IV PRP cut mean pancreatic tumor weight by 85.9% and ovarian tumor weight by ~50%, with no treatment-related adverse events.\n\nIn a UK Specials cohort of 46 advanced-cancer patients, mean survival was 9.0 months versus 5.6 months expected, supporting continued development for pancreatic and ovarian cancers.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Peer-reviewed preclinical validation for PPCB's PRP proenzyme therapy — early-stage but supportive."},"keyFigures":{"drugName":"PRP (Trypsinogen and Chymotrypsinogen A 1:6 proenzyme formulation)","phaseOfTrial":"Preclinical / retrospective clinical cohort","customDimensions":{"uk_cohort_patients":46,"cancer_cell_lines_tested":24,"fibrous_capsule_reduction":"57%","uk_cohort_mean_survival_months":9,"uk_cohort_expected_survival_months":5.6,"tumor_weight_reduction_ovarian_model":"~50%","uk_cohort_survival_beyond_expectancy":"19 patients (41.3%)","tumor_weight_reduction_pancreatic_model":"85.9%"}},"quotedText":"The data published in Scientific Reports provide clear evidence that our synergistic PRP formulation can inhibit key drivers of tumor progression","namedEntities":{"people":[{"name":"Dr. Ralf Brandt","role":"Research and Development Director"},{"name":"James Nathanielsz","role":"company contact"}],"products":["PRP","AngioChamber™"],"companies":[{"name":"Propanc Biopharma, Inc.","ticker":"PPCB","relationship":"filer"},{"name":"Nature Publishing Group / Scientific Reports","relationship":"journal publisher"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Peer-reviewed publication of preclinical (cell-line and orthotopic mouse) data plus retrospective clinical signals from a UK Specials cohort — encouraging but early-stage validation, not a pivotal trial result or regulatory milestone."},"tickerRelevance":{"others":[],"primary":"PPCB"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"preclinical-publication","clinicalStage":"preclinical-plus-retrospective-cohort","issuerAuthored":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Propanc Biopharma announced publication of a peer-reviewed pilot study in Scientific Reports showing potent anti-tumor efficacy of its PRP pancreatic proenzyme formulation across 24 human cancer cell lines.\n\nIn orthotopic mouse models, daily IV PRP cut mean pancreatic tumor weight by 85.9% and ovarian tumor weight by ~50%, with no treatment-related adverse events.\n\nIn a UK Specials cohort of 46 advanced-cancer patients, mean survival was 9.0 months versus 5.6 months expected, supporting continued development for pancreatic and ovarian cancers.","key_figures":{"drugName":"PRP (Trypsinogen and Chymotrypsinogen A 1:6 proenzyme formulation)","phaseOfTrial":"Preclinical / retrospective clinical cohort","customDimensions":{"uk_cohort_patients":46,"cancer_cell_lines_tested":24,"fibrous_capsule_reduction":"57%","uk_cohort_mean_survival_months":9,"uk_cohort_expected_survival_months":5.6,"tumor_weight_reduction_ovarian_model":"~50%","uk_cohort_survival_beyond_expectancy":"19 patients (41.3%)","tumor_weight_reduction_pancreatic_model":"85.9%"}},"named_entities":{"people":[{"name":"Dr. Ralf Brandt","role":"Research and Development Director"},{"name":"James Nathanielsz","role":"company contact"}],"products":["PRP","AngioChamber™"],"companies":[{"name":"Propanc Biopharma, Inc.","ticker":"PPCB","relationship":"filer"},{"name":"Nature Publishing Group / Scientific Reports","relationship":"journal publisher"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:30:11.478Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"preclinical-publication","clinicalStage":"preclinical-plus-retrospective-cohort","issuerAuthored":true}},"durationMs":6257,"modelName":"glm-5.3-flashx"}}